VYNE Therapeutics Files 8-K: Other Events & Exhibits

Ticker: VYNE · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1566044

Vyne Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyVyne Therapeutics Inc. (VYNE)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, corporate-update

TL;DR

VYNE filed an 8-K for other events and exhibits, check for updates.

AI Summary

On January 13, 2025, VYNE Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific new financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing signals that VYNE Therapeutics is providing updates to the SEC, which could contain material information for investors regarding the company's operations or financial condition.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a high-risk situation.

Key Players & Entities

  • VYNE Therapeutics Inc. (company) — Registrant
  • 001-38356 (company) — SEC File Number
  • 45-3757789 (company) — IRS Employer Identification Number
  • Menlo Therapeutics Inc. (company) — Former Company Name
  • Tigercat Pharma, Inc. (company) — Former Company Name

FAQ

What is the primary purpose of this 8-K filing for VYNE Therapeutics Inc.?

The primary purpose of this 8-K filing is to report on "Other Events" and "Financial Statements and Exhibits" as of January 13, 2025.

When was this 8-K report filed?

This 8-K report was filed on January 13, 2025.

What is VYNE Therapeutics Inc.'s state of incorporation?

VYNE Therapeutics Inc. is incorporated in Delaware.

What were VYNE Therapeutics Inc.'s former company names?

VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and Tigercat Pharma, Inc.

What is the business address of VYNE Therapeutics Inc.?

The business address of VYNE Therapeutics Inc. is 685 Route 202/206 N., Suite 301, Bridgewater, New Jersey 08807.

Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-01-13 07:50:28

Key Financial Figures

  • $0.0001 — e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 13, 2025, VYNE Therapeutics Inc. (the " Company ") updated its corporate presentation to include previously announced Phase 1a data for VYN202 and updates on its pipeline programs. The presentation is available through the Company's website, and a copy is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith. Exhibit No. Description 99.1 Presentation, dated January 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYNE THERAPEUTICS INC. Date: January 13, 2025 By: /s/ Mutya Harsch Mutya Harsch Chief Legal Officer and General Counsel 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.